126 related articles for article (PubMed ID: 17671152)
1. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
2. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Horn L; Sandler AB
Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
[TBL] [Abstract][Full Text] [Related]
3. ZD6474--clinical experience to date.
Heymach JV
Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S14-20. PubMed ID: 15928653
[TBL] [Abstract][Full Text] [Related]
4. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies for non-small cell lung cancer: an evolving landscape.
Pal SK; Figlin RA; Reckamp K
Mol Cancer Ther; 2010 Jul; 9(7):1931-44. PubMed ID: 20571071
[TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
Scagliotti G; Govindan R
Oncologist; 2010; 15(5):436-46. PubMed ID: 20427383
[TBL] [Abstract][Full Text] [Related]
7. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
Ryan AJ; Wedge SR
Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S6-13. PubMed ID: 15928657
[TBL] [Abstract][Full Text] [Related]
8. Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer.
Flanigan J; Deshpande H; Gettinger S
Biologics; 2010 Sep; 4():237-43. PubMed ID: 20859451
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
Yoshikawa D; Ojima H; Kokubu A; Ochiya T; Kasai S; Hirohashi S; Shibata T
Br J Cancer; 2009 Apr; 100(8):1257-66. PubMed ID: 19319137
[TBL] [Abstract][Full Text] [Related]
10. Recent development of VEGFR small molecule inhibitors as anticancer agents: A patent review (2021-2023).
Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
[TBL] [Abstract][Full Text] [Related]
11. [Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer].
Zhou C
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):874-9. PubMed ID: 22104223
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma.
Sobczuk P; Cholewiński M; Rutkowski P
Expert Opin Pharmacother; 2024 Apr; 25(5):501-510. PubMed ID: 38607407
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors in lung cancer.
Thomas A; Rajan A; Giaccone G
Hematol Oncol Clin North Am; 2012 Jun; 26(3):589-605, viii. PubMed ID: 22520981
[TBL] [Abstract][Full Text] [Related]
14. New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond.
Gori B; Ricciardi S; Fulvi A; Intagliata S; Del Signore E; de Marinis F
Ther Clin Risk Manag; 2011; 7():429-40. PubMed ID: 22241943
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice.
Santorsola M; Capuozzo M; Nasti G; Sabbatino F; Di Mauro A; Di Mauro G; Vanni G; Maiolino P; Correra M; Granata V; Gualillo O; Berretta M; Ottaiano A
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254839
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
Farhat FS; Houhou W
Ther Adv Med Oncol; 2013 Jul; 5(4):249-70. PubMed ID: 23858333
[TBL] [Abstract][Full Text] [Related]
17. A current review of targeted therapeutics for ovarian cancer.
Campos SM; Ghosh S
J Oncol; 2010; 2010():149362. PubMed ID: 20069122
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review.
Su S; Wu YL
J Hematol Oncol; 2017 Aug; 10(1):147. PubMed ID: 28784178
[TBL] [Abstract][Full Text] [Related]
19. Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors.
Cho DC
Onco Targets Ther; 2013; 6():679-84. PubMed ID: 23788835
[TBL] [Abstract][Full Text] [Related]
20. Salvage treatment with apatinib for advanced non-small-cell lung cancer.
Song Z; Yu X; Lou G; Shi X; Zhang Y
Onco Targets Ther; 2017; 10():1821-1825. PubMed ID: 28367065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
